Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2018

Open Access 01.12.2018 | Research article

Effect of blood pressure and total cholesterol measurement on risk prediction using the Systematic COronary Risk Evaluation (SCORE)

verfasst von: Sabina Ulbricht, Stefan Gross, Eva Brammen, Franziska Weymar, Ulrich John, Christian Meyer, Marcus Dörr

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2018

Abstract

Background

To compare the reproducibility in total cholesterol (TC), systolic blood pressure (BP), and the resulting Systematic COronary Risk Evaluation (SCORE) obtained by an in-office cardio-preventive screening program (SP) and a subsequent program performed in a clinical trial examination center (EP).

Methods

A total of 307 individuals (60.3% female, mean age = 52.8 years) participated. According to TC and BP measurements at the SP and EP, three variables were created: the SCORESP = single BP reading at the SP, the SCOREEP/BP-first = first BP reading at the EP, and the SCOREEP/BP-mean = mean second/third BP reading at the EP. Differences in TC and BP were analyzed. Associations between age, sex and mean differences between the SCORESP and the SCOREEP/BP-first (M1) and the SCOREEP/BP-mean (M2) were analyzed using multivariable linear and quantile regression.

Results

TC and BP values from the SP were significantly higher than those from the EP. Among individuals with a decreased SCORE value at the EP (compared to the SP), younger age was associated with a higher improvement in risk estimation compared with older age. Female sex was associated with higher risk improvement in the SCORE between the SP and the EP compared with male sex. Associations between both demographics and M1 (M2) achieved statistical significance at the 75.0th (50th) percentile.

Conclusions

The reproducibility of results in cardiovascular risk prediction seems to be influenced by the accuracy of BP measurement. It seems that younger individuals and females are more likely to benefit from accuracy compared with older individuals and males.

Background

European guidelines recommend the risk assessment of individuals free from cardiovascular disease (CVD) to be based on the Systematic COronary Risk Evaluation (SCORE) algorithm [1]. The SCORE determines the 10-year risk of a fatal atherosclerotic event using predictors such as age, sex, smoking status, total cholesterol (TC), and systolic blood pressure (BP) [1].
While age and sex can be determined with certainty, there is a degree of uncertainty in the determination of smoking status, TC and blood pressure values [2]. Measurement of TC and BP are subject to error based on their biological variation and methodological issues [3], and the consequences of these measurement issues on CVD risk prediction have been studied. A simulation study indicated that less of the intra-individual variability in the 10-year risk of fatal and non-fatal CVD events (Framingham algorithm) was explained by variation in TC, as most was explained by variation in blood pressure [2]. Further studies confirmed low intra-individual variability in TC up to 10 years [4, 5].
Whereas blood pressure measurement in clinical research is based on highly standardized readings according to established guidelines [4], blood pressure measurement in routine care rarely achieves this high level of accuracy [6, 7], resulting in higher readings compared to standardized measurements [8, 9].
Because the impact of intra-individual variability in TC and blood pressure levels are also related to the measurement standards of SCORE, the aim of this study was to evaluate the reproducibility of both cardiovascular parameters in a sample of individuals aged 40 and 65 years. In addition to the evidence mainly derived from simulation studies [2, 3], reproducibility was determined by comparing TC, BP, and the resulting SCORE values obtained by an in-office cardio-preventive screening program (SP) and a subsequent examination program (EP), performed in a clinical trial examination center. We report findings on the potential differences in TC, BP and the resulting SCORE according to three standardized blood pressure measurements, and we examined if sex and age are related to SCORE reproducibility.

Methods

Design and procedure

This analysis was part of a series of studies (June 2012 to December 2013) investigating different population groups in northeast Germany (general practice patients, job agency clients, and health insurance members) within a stepwise examination program addressing cardiovascular health [10, 11]. The first part of the study, an in-office SP, included a self-administered computerized assessment of cardiovascular risk factors. The opportunity to receive a single blood pressure measurement and non-fasting blood sample was offered. For the second part of the study, the EP, subjects without residence in the study area, with a history of cardiovascular events (myocardial infarction, stroke), vascular intervention, diabetes mellitus, and self-reported body mass index > 35 kg/m2 were excluded. The EP was conducted in the clinical trial examination center at the university hospital and included multiple standardized blood pressure measurements and a non-fasting blood sample.

Selection of participants

The flow of participants has been described in more detail elsewhere [10, 11]. Although individuals aged 40 to 75 years were eligible for the study, the recruited job center clients were between 40 and 65 years old, because the maximum age to register at a job center is 65. Therefore, only participants between 40 and 65 years were considered. A total of 2614 individuals were eligible, and 930 (35.6%) participated in the computer-assisted assessment, which was the first part of the SP. A total of 568 individuals were eligible to participate in the EP, of whom 460 (80.9%) participated. Among them, all individuals with complete data regarding TC and BP at the SP and in the EP were included (N = 307).

Measures

Self-reported data on sex, age and current smoking status were collected within the SP. TC and BP were assessed during both, the SP and the EP. TC was determined from blood samples using standard methodology at the Institute of Clinical Chemistry at the University Medicine Greifswald. A single blood pressure reading of the right arm in the seated position was taken during the SP. During the EP, blood pressure measurement was performed according to a standardized protocol by a certified nurse [12]. The first reading was taken after a 5-min rest. In total, three readings of the right arm and one reading of the left arm were taken at 3-min intervals. For all blood pressure measurements, an Omron 705IT blood pressure monitor (Omron Corporation, Tokyo, Japan) was used.
Variables used for the SCORE, in addition to TC and BP included age, sex, and smoking status. Since the standard of blood pressure measurement might be a key component for the SCORE, three variables were built. The first variable (SCORESP) included the result of TC and a single BP as the basis of the SP. The second variable and the third variable included TC and the first reading of BP (SCOREEP/BP-first) or the mean of the second and third readings of BP (SCOREEP/BP-mean) as the basis of the EP. The calculation of the SCORE was based on the equation scheme suggested by Conroy and colleagues [13].

Statistical analyses

Descriptive statistics were used to characterize the sample. Differences in TC and BP between participants in the SP and the EP were analyzed using linear mixed effect models with the individual as the random factor. All models were adjusted for sex, age, setting of recruitment and period between SP and EP (Mean = 24.1 days, SD = 24.8 days). Given that TC and BP measurements were viewed as the targets, two-way random effects models were used to estimate the Intraclass Correlation Coefficient (ICC, absolute agreement, average measures) with a 95% confidence interval across the two time points. We used the convention in which ICC values between 0.40 and 0.75 indicate fair to good correlation and values of 0.75 or greater indicate excellent correlation [14]. Estimates of the SCORE [1, 15] were calculated according to the three blood pressure measurement protocols. Pearson’s chi-square test was used to analyze if differences between SCORESP and SCOREEP/ BP-first and between SCORESP and SCOREEP/ BP-mean were statistically significant. Further, we performed multi-variable linear regression analyses, which estimated the average effect of age and sex on differences in SCORE (Outcome between SCORESP and SCOREEP/BP-first (Model 1) and between SCORESP and SCOREEP/ BP-mean (Model 2). Subsequently, differences in SCORE and covariates (age, sex) were also used in quantile regression for a more in-depth evaluation of effect size [16]. Compared with linear regression based on the conditional mean, quantile regression is more suitable in cases where the effect of covariates differs at different levels of the dependent variable. Thus, we tested whether potential associations of sex and age vary across the 2.5th to the 97.5th percentiles of individual SCORE differences. All regression models were adjusted for the setting of recruitment, duration between the SP and EP, and the SCORE value at SP. A p value < .05 was considered statistically significant. All analyses were carried out using Stata 14.1.

Results

Sociodemographic characteristics of the participants

The proportions of male individuals recruited via general practices (n = 154), from health insurance (n = 96), and from job agencies (n = 57) were 41.8%, 31.3 and 53.3%, respectively. The mean age was higher among individuals recruited from health insurance (56.6 ± 7.0) compared to individuals recruited via general practices (52.6 ± 7.3, p < 0.001) and job agencies (50.2 ± 5.8, p < 0.001). The prevalence of smoking was higher among individuals recruited from job agencies (58.7%) compared with those recruited from health insurance (15.7%, p < 0.001) and general practices (26.6%, p < 0.001).

Total cholesterol, blood pressure and cardiovascular risk prediction using SCORE

The ICCs indicated an excellent agreement of TC and BP between SP and EP with one exception; the ICC for systolic blood pressure at the SP and the first reading in the EP was found to be fair to good (Table 1). However, analysis revealed that TC and BP values from the SP were significantly higher than those from the EP. Both findings were also seen for all three settings when analyzed separately (See Additional file 1: Table S1 and Additional file 2: Table S2).
Table 1
Differences in total cholesterol (mmol/l) and systolic blood pressure (mmHg) between the in-office cardio-preventive screening and the clinical examination programa
 
In-office screening program
Clinical examination programb
Intraclass correlation
Clinical examination programc
Intraclass correlation
Mean (SE)
Mean (SE)
Mean difference (SE)
p-value
ICC
95%-CI
Mean(SE)
Mean differencec (SE)
p-value
ICC
95%-CI
Total cholesterol
5.75 (0.63)
5.54 (0.58)
0.21 (0.03)
< .001
.91
.87–.94
     
Systolic blood pressure
140.48 (1.00)
133.97 (0.99)
6.51 (0.82)
< .001
.60
.27–.75
128.63 (0.87)
11.86 (0.83)
< .001
. 91
.84–.95
SE standard error, IC intraclass correlation coefficient, CI confidence interval
aAdjusted for sex, age, setting of recruitment and duration between the in-office screening and the clinical examination program. The value of systolic blood pressure measurement corresponds to the first readingb, to the mean of the second and third readingc
Further, the calculation of the SCORE on the basis of measurements at the SP resulted in significantly higher proportions of individuals at moderate or high risk compared to calculation on the basis of measurements at the EP (Table 2).
Table 2
Proportions in Systematic COronary Risk Evaluation categories (n = 307) at the in-office cardio-preventive screening program and at the clinical examination program
 
In-office screening program
Clinical examination program
SCORESP
SCOREEP/BP-first
SCOREEP/BP-mean††
n
%
n
%
n
%
Low risk
 SCORE < 1%
131
42.7
143
46.6
157
51.1
Moderate risk
 SCORE ≥ 1% and < 5%
154
50.2
151
49.2
143
46.6
High risk
 SCORE ≥ 5%
22
7.1
13
4.2
7
2.3
SCORESP was based on total cholesterol and the single reading of systolic blood pressure at the in-office screening program. SCOREEP/BP-first, (SCOREEP/BP-mean) were based on total cholesterol and the first reading (the mean of the second and third reading) of systolic blood pressure at the clinical examination program
Pearson chi2 = 330.996; p < .001, comparison between SCORESP and SCOREEP/BP-first
††Pearson chi2 = 159.592; p < .001, comparison between SCORESP and SCOREEP/BP-mean
Table 3 gives a comparison of the coefficients obtained using multivariable linear regression and quantile regression. Multivariable linear regression analysis revealed that sex and age were not associated with mean differences between SCORESP and SCOREEP/BP-first (Model 1) and between SCORESP and SCOREEP/BP-mean (Model 2). According to the quantile regression analysis, age was negatively associated with the 50.0th percentile (Model 2 only) and with the 75.0th and the 90.0th percentiles (both Models) of mean differences in SCORE. Female sex was positively associated with the 50.0th percentile (Model 2 only) and with the 75.0th and the 90.0th percentiles (both Models) of mean differences in SCORE.
Table 3
Associations between age, sex and the mean differences in Systematic COronary Risk Evaluation between the in-office cardio-preventive screening program and clinical examination programa
 
Linear regression
Quantile regression
 
q10
q25
q50
q75
q90
b [95% CI]
b [95% CI]
b [95% CI]
b [95% CI]
b [95% CI]
b [95% CI]
Model 1: Difference between SCORESP and SCOREEP/BP-first
 Age
−0.012 [−0.048, 0.025]
−0.013 [− 0.043, 0.016]
−0.009 [− 0.026, 0.008]
−0.013 [− 0.029, 0.003]
−0.021 [− 0.033, − 0.009]
−0.011 [− 0.020, − 0.002]
 Sex
0.025 [− 0.388, 0.438]
0.045 [− 0.330, 0.420]
0.084 [− 0.127, 0.295]
0.111 [− 0.094, 0.317]
0.204 [0.051, 0.356]
0.153 [0.039, 0.268]
Model 2: Difference between SCORESP and SCOREEP/BP-mean
 Age
− 0.003 [− 0.041, 0.035]
−0.003 [− 0.014, 0.008]
−0.004 [− 0.024, 0.015]
−0.014 [− 0.262, − 0.002]
−0.017 [− 0.028, − 0.006]
−0.022 [− 0.030, − 0.129]
 Sex
0.075 [− 0.349, 0.499]
0.046 [0.103, 0.194]
0.132 [− 0.121, 0.385]
0.176 [0.020, 0.332]
0.202 [0.059, 0.344]
0.247 [0.135, 0.359]
Bold coefficients indicate significant effects
q quantile, b coefficient, CI confidence interval
aAnalyses were adjusted for setting of recruitment, duration between cardio-preventive screening and clinical examination program, and the SCORE value at the in-office screening program. SCORESP was based on total cholesterol and the single reading of systolic blood pressure at the in-office screening program. SCOREEP/BP-first (SCOREEP/BP-mean) were based on total cholesterol and the first reading (the mean of the second and third reading) of systolic blood pressure at clinical examination program
The distribution of mean differences in the SCORE (∆ SCORE) between SCORESP and SCOREEP/BP-mean in relation to the number of individuals is presented in Fig. 1. While ∆ SCORE < 0 determined an increased SCORE value, ∆ SCORE > 0 determined a decreased SCORE value, both at the EP and in comparison to the SP.

The relation of sex and age to SCORE reproducibility

The variation in regression coefficients for age and sex according to the 2.5th to the 97.0th percentiles in Model 2 are presented in Fig. 2a and b. As shown in Fig. 2a, the inverse association between the mean SCORE difference and age became stronger and statistically significant only in the higher percentiles of the outcome variable, e.g., at the 97.0th percentile (Mean SCORE difference = 3.141, b = − 0.026, 95%-CI: -0.048, − 0.0038), where the age effect was more pronounced compared to the 50.0th percentile (Mean SCORE difference = 0.182, b = − 0.014. 95%-CI: -0.262, − 0.002). This finding means that in individuals with lower risk estimations at the EP, younger individuals have a higher risk estimation improvement compared to older individuals due to the highly-standardized measurement regime at the EP.
As shown in Fig. 2b the positive association between female sex and mean differences in SCORE strengthened in the higher percentiles again and achieved statistical significance at the 50.0th percentile. This finding means that, in individuals with lower risk estimation at the EP, females have a higher risk estimation improvement compared to males.

Discussion

The three main findings of our study are as follows: (1) The results of TC and BP measurement varied between the SP and EP with lower values derived from measurements at EP. (2) The proportions of individuals at moderate or high risk according to the SCORE at the EP were lower compared to the proportions at the SP. (3) The strength of the association between age, sex and the mean differences in the SCORE between the SP and the EP varied substantially across the distribution of our outcome, which was the mean difference in the SCORE.
The impact of combined risk factors for CVD risk estimation is emphasized in the guidelines recently published by the European Society of Cardiology [1]. While age, sex and smoking status were stable due to the short time period between the SP and the EP, our data indicated a relative difference of 3.6% (0.21 mmol/l) in TC between both measurements. Observed changes in TC measurements are often due to errors related to processing, storage and laboratory analyses and biological variability [17] and/or a short-term biological variability up to 7.0% [18]. However, the mean of BP (140.5 mmHg) obtained by a single measurement at the SP was found to be decreased by 4.6% (6.5 mmHg) at the EP when adhering to a resting time of 5 min prior to the first measurement and by 11.9% (8.4 mmHg) when calculating the mean of the second and third measurements. Given our results and that the majority of studies used guidelines proposed repeated BP measurements, taking a single measurement without resting period should be discouraged in clinical routine care. However, increasing the accuracy of BP measurement in clinical routine care seems to be a challenge because 77% of physicians took BP reading without any resting time [19].
The error introduced by low standardization of blood pressure measurement at the SP in addition to biological variation [20] affects the second finding of our study, the variability on cardiovascular risk prediction using SCORE. Imprecision in calculation is important, especially if the SCORE is close to the threshold of high risk, as subjects may benefit from intensive counseling and/or drug treatment. However, similar to the results of a simulation study, moderate- and high-risk individuals in our study were more likely subjected to errors in the SCORE than low-risk participants [3].
The third main finding of this study is related to the differential impact of age and sex across the distribution of mean differences in the SCORE between the SP and the EP. Our results add to the literature by showing that neither sex nor age were found to be associated with mean differences in the SCORE across the whole distribution.
When linear multivariable regression analyses were employed, the results failed to capture the differential association found when using quantile regression. The mean differences in the SCORE between the SP and the EP (SCORE EP/SPB-mean) were 0.182 at the 50.0th percentile and 3.141 at the 97.0th percentile. Among individuals with a decreased SCORE value at the EP (compared to the SP), younger age was associated with a higher decrease and therefore with a higher improvement in risk estimation compared with older age. The association was strongest at the higher percentiles of the outcome. Furthermore, our results suggest that female sex is associated with higher risk improvement in the SCORE between the SP and the EP compared with male sex. However, the association was found to be significant only for percentiles ≥50.0th of the outcome. It seems that younger individuals and females are more dependent on the measurement situation (unscheduled in-office examination program vs. scheduled clinical trial center examination program) and/or the measurement regimes. The present study linked CVD risk prediction data assessed close to routine practice to those assessed via highly standardized measurement in a clinical trial examination center. Thus, our results extend the evidence regarding the effects of inter-individual variability in TC and BP on CVD risk estimation as shown in simulation studies [2, 3].
However, our study is subject to at least four limitations. First, all findings are based on a relatively small sample of individuals aged between 40 and 65 years. Second, individuals eligible for the EP were only those without pre-existing diabetes and cardiovascular disease, resulting in a reduced number of individuals categorized as high risk according to the SCORE. Furthermore, smokers were less likely to participate in the EP [10], which might have contributed to the low number of high-risk individuals. Third, other potential confounding factors including those related to modifiable risk factors (e. g. physical activity) were not investigated in the present study.

Conclusions

The reproducibility of results in cardiovascular risk prediction using SCORE seems to be influenced particularly by the accuracy of BP measurement. Younger individuals and females are more likely to benefit from a resting period prior to the first BP reading and in addition from two more BP readings, taken at 3-min intervals, compared with older individuals and males.

Acknowledgements

The authors appreciate the support by the statutory health insurance company, the job centers, and the general practices with regards to the participant recruitment.

Funding

This research was supported by the German Centre for Cardiovascular Research (DZHK), Grant No. 81/Z540100152.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author on request. Researchers requesting the data will be required to sign a contract ensuring data usage in compliance with the statement given in the informed consent procedure and with the German data protection law, that the data will not be transferred to others, and that the data will be deleted after the intended analysis has been completed. To comply with the statement given in the informed consent, the use of the data is restricted to research related to cardiovascular-research questions. We cannot ensure to prevent use for other purposes when uploading the data for public access.
This study was approved by the clinical ethical committee of the University Medicine Greifswald, Germany (protocol number BB41/12). Written informed consent was obtained from all individuals included in the study prior to participation.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.CrossRefPubMedPubMedCentral Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Marshall T. The effect of blood pressure and cholesterol variability on the precision of Framingham cardiovascular risk estimation: a simulation study. J Hum Hypertens. 2010;24(10):631–8.CrossRefPubMed Marshall T. The effect of blood pressure and cholesterol variability on the precision of Framingham cardiovascular risk estimation: a simulation study. J Hum Hypertens. 2010;24(10):631–8.CrossRefPubMed
3.
Zurück zum Zitat Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk. 2002;9(4):183–90.CrossRefPubMed Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk. 2002;9(4):183–90.CrossRefPubMed
4.
Zurück zum Zitat Jackson SE, van Jaarsveld CH, Beeken RJ, Gunter MJ, Steptoe A, Wardle J. Four-year stability of anthropometric and cardio-metabolic parameters in a prospective cohort of older adults. Biomark Med. 2015;9(2):109–22.CrossRefPubMed Jackson SE, van Jaarsveld CH, Beeken RJ, Gunter MJ, Steptoe A, Wardle J. Four-year stability of anthropometric and cardio-metabolic parameters in a prospective cohort of older adults. Biomark Med. 2015;9(2):109–22.CrossRefPubMed
5.
Zurück zum Zitat Angelow A, Schmidt CO, Dörr M, Chenot JF. Utility of repeat serum cholesterol measurements for assessment of cardiovascular risk in primary prevention. Eur J Prev Cardiol. 2016;23(6):628–35.CrossRefPubMed Angelow A, Schmidt CO, Dörr M, Chenot JF. Utility of repeat serum cholesterol measurements for assessment of cardiovascular risk in primary prevention. Eur J Prev Cardiol. 2016;23(6):628–35.CrossRefPubMed
6.
Zurück zum Zitat Campbell NR, Culleton BW, McKay DW. Misclassification of blood pressure by usual measurement in ambulatory physician practices. Am J Hypertens. 2005;18(12 Pt 1):1522–7.CrossRefPubMed Campbell NR, Culleton BW, McKay DW. Misclassification of blood pressure by usual measurement in ambulatory physician practices. Am J Hypertens. 2005;18(12 Pt 1):1522–7.CrossRefPubMed
7.
Zurück zum Zitat Sebo P, Pechere-Bertschi A, Herrmann FR, Haller DM, Bovier P. Blood pressure measurements are unreliable to diagnose hypertension in primary care. J Hypertens. 2014;32(3):509–17.CrossRefPubMed Sebo P, Pechere-Bertschi A, Herrmann FR, Haller DM, Bovier P. Blood pressure measurements are unreliable to diagnose hypertension in primary care. J Hypertens. 2014;32(3):509–17.CrossRefPubMed
8.
Zurück zum Zitat Powers BJ, Olsen MK, Smith VA, Woolson RF, Bosworth HB, Oddone EZ. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med. 2011;154(12):781–8. W-289-790CrossRefPubMed Powers BJ, Olsen MK, Smith VA, Woolson RF, Bosworth HB, Oddone EZ. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med. 2011;154(12):781–8. W-289-790CrossRefPubMed
9.
Zurück zum Zitat Tolonen H, Koponen P, Naska A, Mannisto S, Broda G, Palosaari T, Kuulasmaa K, Project EP. Challenges in standardization of blood pressure measurement at the population level. BMC Med Res Methodol. 2015;15:33.CrossRefPubMedPubMedCentral Tolonen H, Koponen P, Naska A, Mannisto S, Broda G, Palosaari T, Kuulasmaa K, Project EP. Challenges in standardization of blood pressure measurement at the population level. BMC Med Res Methodol. 2015;15:33.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Guertler D, Meyer C, Dörr M, Braatz J, Weymar F, John U, Freyer-Adam J, Ulbricht S. Reach of individuals at risk for cardiovascular disease by proactive recruitment strategies in general practices, job centers, and health insurance. Int J Behav Med. 2017;24(1):153–60.CrossRefPubMed Guertler D, Meyer C, Dörr M, Braatz J, Weymar F, John U, Freyer-Adam J, Ulbricht S. Reach of individuals at risk for cardiovascular disease by proactive recruitment strategies in general practices, job centers, and health insurance. Int J Behav Med. 2017;24(1):153–60.CrossRefPubMed
11.
Zurück zum Zitat Weymar F, Braatz J, Guertler D, van den Berg N, Meyer C, John U, Felix SB, Dörr M, Ulbricht S. Characteristics associated with non-participation in 7-day accelerometry. Prev Med Rep. 2015;2:413–8.CrossRefPubMedPubMedCentral Weymar F, Braatz J, Guertler D, van den Berg N, Meyer C, John U, Felix SB, Dörr M, Ulbricht S. Characteristics associated with non-participation in 7-day accelerometry. Prev Med Rep. 2015;2:413–8.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294–307.CrossRefPubMed Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294–307.CrossRefPubMed
13.
Zurück zum Zitat Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.CrossRefPubMed Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.CrossRefPubMed
14.
Zurück zum Zitat Rosner B. Fundamentals of biostatistics. Boston: Brooks/ Cole; 2011. Rosner B. Fundamentals of biostatistics. Boston: Brooks/ Cole; 2011.
15.
Zurück zum Zitat European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818.CrossRef European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818.CrossRef
16.
Zurück zum Zitat Koenker R. Quantile Regression. New York, NY: Camebridge University Press; 2005.CrossRef Koenker R. Quantile Regression. New York, NY: Camebridge University Press; 2005.CrossRef
17.
Zurück zum Zitat Perera R, McFadden E, McLellan J, Lung T, Clarke P, Perez T, Fanshawe T, Dalton A, Farmer A, Glasziou P, et al. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technol Assess. 2015;91(0):1–401.CrossRef Perera R, McFadden E, McLellan J, Lung T, Clarke P, Perez T, Fanshawe T, Dalton A, Farmer A, Glasziou P, et al. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technol Assess. 2015;91(0):1–401.CrossRef
18.
Zurück zum Zitat Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, Investigators LS. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med. 2008;148(9):656–61.CrossRefPubMed Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, Investigators LS. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med. 2008;148(9):656–61.CrossRefPubMed
19.
Zurück zum Zitat Levy J, Gerber LM, Wu X, Mann SJ. Nonadherence to recommended guidelines for blood pressure measurement. J Clin Hypertens. 2016;18(11):1157–61.CrossRef Levy J, Gerber LM, Wu X, Mann SJ. Nonadherence to recommended guidelines for blood pressure measurement. J Clin Hypertens. 2016;18(11):1157–61.CrossRef
20.
Zurück zum Zitat Musini VM, Wright JM. Factors affecting blood pressure variability: lessons learned from two systematic reviews of randomized controlled trials. PLoS One. 2009;4(5):e5673.CrossRefPubMedPubMedCentral Musini VM, Wright JM. Factors affecting blood pressure variability: lessons learned from two systematic reviews of randomized controlled trials. PLoS One. 2009;4(5):e5673.CrossRefPubMedPubMedCentral
Metadaten
Titel
Effect of blood pressure and total cholesterol measurement on risk prediction using the Systematic COronary Risk Evaluation (SCORE)
verfasst von
Sabina Ulbricht
Stefan Gross
Eva Brammen
Franziska Weymar
Ulrich John
Christian Meyer
Marcus Dörr
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2018
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0823-3

Weitere Artikel der Ausgabe 1/2018

BMC Cardiovascular Disorders 1/2018 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.